Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by equities researchers at Citigroup in a research report issued to clients and investors on Wednesday.

A number of other equities research analysts also recently weighed in on BAYN. Sanford C. Bernstein set a €129.00 ($153.57) price target on Bayer and gave the stock a “buy” rating in a research note on Wednesday. Warburg Research set a €121.00 ($144.05) price target on Bayer and gave the stock a “neutral” rating in a research note on Thursday, January 11th. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the stock a “neutral” rating in a research note on Friday, January 12th. Jefferies Group set a €125.00 ($148.81) price target on Bayer and gave the stock a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. set a €128.00 ($152.38) price target on Bayer and gave the stock a “buy” rating in a research note on Wednesday, January 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Bayer has a consensus rating of “Buy” and an average price target of €121.67 ($144.84).

Shares of Bayer (FRA BAYN) opened at €103.48 ($123.19) on Wednesday. Bayer has a one year low of €99.69 ($118.68) and a one year high of €123.82 ($147.40). The firm has a market capitalization of $85,870.00 and a PE ratio of 27.74.

TRADEMARK VIOLATION NOTICE: “Bayer (BAYN) Given “Buy” Rating at Citigroup” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/01/17/bayer-bayn-given-buy-rating-at-citigroup.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.